Latest Articlesddd

PTC Therapeutics: U.S. FDA Approved a First-Time Gene Therapy Administered directly into the Brain to Treat Children and Adults

November 14, 2024 0

PTC Therapeutics Announcement Today, November 13, 2024, PTC Therapeutics, Inc. (PTCT) announced that the U.S. FDA accelerated …

Altimmune Third Quarter 2024 Financial Results and Provides Business Update  

November 13, 2024 0

Altimmune Third Quarter Financial Results Yesterday, October 12, 2024, Altimmune (ALT) announced financial results for the …

BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million

November 12, 2024 0

BioStem Technologies Third Quarter 2024 Report Today, November 12, 2024, BioStem Technologies (BSEM), a leading MedTech …

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update 

November 12, 2024 0

InflaRX  In March 2024, InflaRx Biopharmaceutical (IFRX) announced that it will pursue two initial immuno-dermatology indications …

Gilead Sciences 3rd Quarter Financial Results

November 7, 2024 0

From Gilead Sciences  Gilead Sciences (GILD) Chairman and CEO Daniel O’Day, said, “Gilead’s third-quarter results are …

Anavex Life Sciences: Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial 

November 1, 2024 0

Anavex Life Sciences Anavex Life Sciences (AVXL) presented new data from the Phase IIb/III study showing …

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the Treatment of Uncomplicated Urinary Tract Infections

October 29, 2024 0

Iterum Therapeutics US FDA Approval On October 25, 2024, Iterum Therapeutics (ITRM) announced that the U.S. …

Some Stories To Know About Vera and Viking Therapeutics

October 29, 2024 0

Vera Therapeutics and Viking Therapeutics Today, October 29, the market stocks’ prices moved south, including good …

Vera Therapeutics Announces Long-Term Improvement Results in Treating Berger’s Nephritis

October 28, 2024 0

Vera Therapeutics Announcement Two days ago, Vera Therapeutics, Inc. (VERA) announced data from its ORIGIN Phase …

Intellia Therapeutics: Positive Results from NTLA-2002 in CRISPR Gene Editing Treatment for Hereditary Angioedema

October 25, 2024 0

Intellia Therapeutics Intellia Therapeutics (NTLA) is a clinical-stage gene editing company focused on revolutionizing medicine with …

The United States FDA Approved Astellas’ product VYLOY in Combination with Fluoropyrimidine and Platinum-Containing Chemotherapy for the First-Line Treatment of Adults with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

October 21, 2024 0

Astellas Pharma Inc Announcement Tokyo, Oct. 18, 2024, Astellas Pharma Inc. (TSE: 4503, President and CEO: …

Vertex Pharmaceuticals to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the ASA Annual Meeting.

October 18, 2024 0

Vertex Pharmaceuticals Announcement October 18, 2024, Vertex Pharmaceuticals  (VRTX) today announced that the company will present …

U.S. FDA Approves AbbVie’s VYALEV™ for Adults Living with Advanced Parkinson’s Disease

October 17, 2024 0

AbbVie FDA Approval for VYALEV for Parkinson’s Disease AbbVie (ABBV) announced that the U.S. FDA  approved …

Aligos Therapeutics is on the Way to Treating MASH and More

October 16, 2024 0

Aligos Therapeutics On September 20, 2024, we posted a press release stating that Aligos Therapeutics (ALGS) …

Novo Nordisk Launches New Initiative To Prevent Childhood Obesity In Disadvantaged Urban Communities

October 11, 2024 0

Novo Nordisk Childhood Obesity Prevention Initiative  From Bagsværd, Denmark, on October 8, 2024, Novo Nordisk (NVO) …

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

October 10, 2024 0

Intellia Therapeutics Announcement Intellia Therapeutics (NTLA) announced the initiation of HAELO, a pivotal Phase 3 study …

AstraZeneca Strengthens its Cardiovascular Pipeline with Agreement for a Pre-Clinical Novel Lipid-Lowering Therapy

October 8, 2024 0

AstraZeneca Agreement with CSPC Pharmaceutical Group Yesterday, October 7, 2024, AstraZeneca (AZN) announced it entered into …

Vera Therapeutics Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

October 2, 2024 0

 Vera Therapeutics in the NEWS Today, October 02, 2024, Vera Therapeutics (VERA) announced the expansion of …

Johnson & Johnson Rolls Out New TECNIS Odyssey, Next-Generation Intraocular Lens, Offering Cataract Patients Precise Vision at Every Distance in Any Lighting

September 30, 2024 0

Johnson & Johnson New TECNIS Odyssey On September 30, 2024, Johnson & Johnson (JNJ) announced expanding …

The United States FDA Approved Bristol Myers Squibb’s COBENFY™ – A First-In-Class Muscarinic Agonist for Schizophrenia in Adults

September 27, 2024 0

Bristol-Myers Squibb COBENFY™ Approval Bristol Myers Squibb (BMY) announced that the U.S. FDA has approved COBENFY™ …